Gossamer Bio, Inc. (GOSS) Stock Analysis & Investment Frameworks
Gossamer Bio, Inc. (GOSS) stock analysis on Invetso. Review Gossamer Bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Gossamer Bio, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Gossamer Bio, Inc. Key Financial Metrics
- Market Cap: $59.70M
- Revenue: $48.47M
- ROE: 108.75%
- ROIC: 670.05%
- Dividend Yield: N/A
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc. Investment Frameworks
Invetso analyzes Gossamer Bio, Inc. (GOSS) across the following frameworks:
- Gossamer Bio, Inc. 10Y Growth Potential
- Gossamer Bio, Inc. Scenario Analysis
- Gossamer Bio, Inc. Risks & Opportunities
- Gossamer Bio, Inc. Economic Moat
- Gossamer Bio, Inc. Business Model
- Gossamer Bio, Inc. Management
- Gossamer Bio, Inc. SWOT Analysis
- Gossamer Bio, Inc. Porter's 5 Forces
- Gossamer Bio, Inc. PESTLE Analysis
- Gossamer Bio, Inc. ESG Analysis